Soleil Boughton Sells 2,503 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the sale, the insider now owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.17, for a total value of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total value of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total value of $229,075.17.

Hims & Hers Health Stock Up 3.5 %

Shares of HIMS opened at $15.51 on Thursday. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $17.16. The company has a market capitalization of $3.32 billion, a price-to-earnings ratio of -141.00 and a beta of 0.91. The stock’s 50-day moving average price is $12.41 and its 200-day moving average price is $9.24.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. During the same quarter in the prior year, the business earned ($0.05) earnings per share. The company’s revenue was up 47.4% compared to the same quarter last year. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.1 EPS for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the topic of several recent analyst reports. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Truist Financial upped their target price on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Piper Sandler upped their target price on Hims & Hers Health from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Tuesday, February 27th. Guggenheim increased their price objective on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Tigress Financial increased their price objective on Hims & Hers Health from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 5th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Moderate Buy” and a consensus price target of $13.45.

Institutional Trading of Hims & Hers Health

Hedge funds have recently modified their holdings of the stock. CM Wealth Advisors LLC purchased a new stake in shares of Hims & Hers Health in the second quarter worth about $25,000. Point72 Middle East FZE purchased a new position in Hims & Hers Health during the fourth quarter worth approximately $29,000. Captrust Financial Advisors boosted its position in Hims & Hers Health by 1,827.4% during the first quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after purchasing an additional 6,414 shares in the last quarter. Harbour Investments Inc. boosted its position in Hims & Hers Health by 427.9% during the third quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock worth $44,000 after purchasing an additional 5,670 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new position in Hims & Hers Health during the first quarter worth approximately $46,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.